Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Biotechnology
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company... see more

Recent & Breaking News (CSE:AWKN)

Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

Newsfile December 15, 2022

Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)

Newsfile December 13, 2022

Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

Newsfile December 1, 2022

Awakn Life Sciences Announces Location for Larger Oslo Clinic

Newsfile November 23, 2022

Awakn Life Sciences Announces Closing of Private Placement

Newsfile November 17, 2022

Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York

Newsfile November 9, 2022

Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations

Newsfile October 25, 2022

Awakn Life Sciences Reports Strong Q2 2022 Results

Newsfile September 15, 2022

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program

Newsfile September 12, 2022

Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program

Newsfile August 25, 2022

Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

Newsfile August 18, 2022

Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Newsfile August 15, 2022

 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

Business Wire August 15, 2022

Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

Newsfile July 20, 2022

Awakn Life Sciences Provides a Business and Corporate Update

Newsfile July 15, 2022

Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder

Newsfile July 5, 2022

Awakn Life Sciences to Present in Upcoming June 2022 Conferences

Newsfile June 17, 2022

Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022

Newsfile June 14, 2022

Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO

Newsfile June 7, 2022

Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder

Newsfile June 2, 2022